Senta Frol, MD, PhD, University Medical Centre Ljubljana, Ljubljana, Slovenia, reviews the current standard operating procedure (SOP) for idarucizumab reversal of dabigatran anticoagulation in ischemic and hemorrhagic stroke. Idarucizumab application in stroke patients taking dabigatran is safe and results in decreased mortality rate and improved functional outcomes. Reversal of dabigatran with idarucizumab is beneficial before intravenous thrombolysis in ischemic stroke patients and patients with intracranial hemorrhage since it may prevent hematoma growth, thereby improving functional outcomes in both groups. This interview took place at the 17th World Congress on Controversies in Neurology (CONy) in Dubrovnik, Croatia.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.